Therefore, the current study aims to compare haematological parameter changes, including Hct, RBC and Hb, between patients with T2DM treated with SGLT‐2i and TRT for hypogonadism (SGLT2‐i (+) group) and those treated for T2DM with any anti‐diabetic treatment other than SGLT2i with TRT (SGLT‐2i (−) group). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.